Literature DB >> 2390480

Deoxycoformycin in the treatment of mature B-cell malignancies.

C Dearden1, D Catovsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2390480      PMCID： PMC1971740          DOI： 10.1038/bjc.1990.217

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  14 in total

1.  2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

Authors:  L D Piro; C J Carrera; E Beutler; D A Carson
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

2.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

Review 3.  Enzyme patterns in normal lymphocyte subpopulations, lymphoid leukaemias and immunodeficiency syndromes.

Authors:  A V Hoffbrand; D D Ma; A D Webster
Journal:  Clin Haematol       Date:  1982-10

Review 4.  Current approaches to the chemotherapy of B-cell chronic lymphocytic leukemia: a review.

Authors:  B D Cheson
Journal:  Am J Hematol       Date:  1989-09       Impact factor: 10.047

5.  The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

Authors:  M R Grever; M F Siaw; W F Jacob; J A Neidhart; J S Miser; M S Coleman; J J Hutton; S P Balcerzak
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

Review 6.  2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.

Authors:  P J O'Dwyer; B Wagner; B Leyland-Jones; R E Wittes; B D Cheson; D F Hoth
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

7.  The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.

Authors:  J B Johnston; R I Glazer; L Pugh; L G Israels
Journal:  Br J Haematol       Date:  1986-07       Impact factor: 6.998

8.  Low-dose deoxycoformycin in lymphoid malignancy.

Authors:  M R Grever; J M Leiby; E H Kraut; H E Wilson; J A Neidhart; R L Wall; S P Balcerzak
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

9.  Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.

Authors:  H G Prentice; J F Smyth; K Ganeshaguru; B Wonke; K F Bradstock; G Janossy; A H Goldstone; A V Hoffbrand
Journal:  Lancet       Date:  1980-07-26       Impact factor: 79.321

10.  Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

Authors:  A S Spiers; D Moore; P A Cassileth; D P Harrington; F J Cummings; R S Neiman; J M Bennett; M J O'Connell
Journal:  N Engl J Med       Date:  1987-04-02       Impact factor: 91.245
View more
  5 in total

Review 1.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 3.  Achieving optimal outcomes in chronic lymphocytic leukaemia.

Authors:  T J Hamblin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

Authors:  S A Johnson; D Catovsky; J A Child; A C Newland; D W Milligan; R Janmohamed
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 5.  Current approaches to the treatment and management of chronic lymphocytic leukaemia.

Authors:  E Montserrat; C Rozman
Journal:  Drugs       Date:  1994       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.